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Background: TREM2 is a microglial receptor, recently identified as a genetic risk factor for late onset AD.
Results: Sequential proteolytic processing of TREM2 involves ectodomain shedding and intramembranous cleavage by-secre-
tase and affects signaling via its adaptor protein DAP12.
Conclusion: -Secretase-mediated intramembranous proteolysis modulates TREM2 signaling.
Significance: Inhibition of -secretase could impair TREM2 function in neuroinflammation.
Triggering receptor expressed on myeloid cells-2 (TREM2)
and its signaling adaptor protein TYROBP/DAP12 play impor-
tant roles in signal transduction in dendritic cells, osteoclasts,
tissue macrophages, and microglia. Recently, TREM2 variants
have been shown to be linked to late onset Alzheimer disease.
Here, we demonstrate that TREM2 undergoes sequential pro-
teolytic processing by ectodomain shedding and intramem-
brane proteolysis. The C-terminal fragment (CTF) of TREM2
generated by ectodomain shedding is cleaved by -secretase.
Importantly, pharmacologic and genetic -secretase inhibition
resulted in accumulation of TREM2 CTF at the plasma mem-
brane that also interacts with the signaling adaptor protein
DAP12. Thus, the accumulated TREM2 CTF thereby might
limit the interaction of DAP12 with the functional full-length
receptor, resulting in decreased DAP12 phosphorylation and
impairedmetabolismof phosphatidylinositol 4,5-bisphosphate.
Together, these data demonstrate -secretase-mediated intramem-
branous proteolysis of TREM2 and functionally link two Alzheimer
disease-associatedproteins inone signalingpathway.
The triggering receptor expressed on myeloid cells-2
(TREM2)2 is a 40-kDa type I membrane glycoprotein with a
single extracellular immunoglobulin-like domain, one trans-
membrane domain, and a short cytoplasmatic tail. Although
the cytoplasmic domain of TREM2 does not contain an overt
amino acid-based signaling motif, its transmembrane domain
interacts with the adaptor protein TYROBP/DNAX-activating
protein of 12 kDa (DAP12) via electrostatic interaction (1, 2).
TREM2 was originally identified on monocyte-derived den-
dritic cells (3), but was later also detected on several myeloid
cell types including osteoclasts, tissuemacrophages, andmicro-
glia (1). TREM2 is localized predominantly in the Golgi com-
plex, but also shuttles to and from the cell surface in endocytic
and exocytic vesicles (4, 5).
DAP12 is a type I transmembrane protein, which acts as a
signaling adaptor protein forTREM2and anumber of other cell
surface receptors (6). The cytoplasmic domain of DAP12 con-
tains an immunoreceptor tyrosine activation motif (ITAM) (1,
7). After activation of the interacting receptor, DAP12 under-
goes phosphorylation at the two conserved ITAM tyrosine res-
idues by Src kinases. Subsequent recruitment and activation of
the Syk protein kinase trigger downstream signaling pathways,
including the activation of mitogen-activated protein kinase
(MAPK) and phospholipase C (PLC) (7).
The physiological relevance of TREM2 and DAP12 is dem-
onstrated by loss-of-function mutations of either gene that
cause polycystic lipomembranous osteodysplasia with scleros-
ing leukoencephalopathy (PLOSL or Nasu-Hakola disease)
associated with presenile dementia in the fourth decade of life
in homozygous carriers (8, 9). Notably, rare variants of TREM2
in the heterozygous state have recently been identified by
exome sequencing to increase the risk of late onset Alzheimer
disease (LOAD) (10–14) and frontotemporal lobe dementia
(15). Although the population frequency of the TREM2 R47H
variant in the cohorts studied was much lower compared with
the most common genetic risk factor, the apolipoprotein 4
allele, the effects of both factors on the individual risk to
develop LOAD were comparable (10, 11). TREM2 was also
found to be up-regulated inmicroglia of amyloid precursor pro-
tein transgenic mouse models (10, 16, 17).
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Here, we demonstrate that a C-terminal fragment of TREM2
generated by ectodomain shedding represents a novel substrate
of the AD-associated -secretase. Interestingly, loss of -secre-
tase activity leads to accumulation of TREM2 CTFs, impairing
phosphorylation of the TREM2 adaptor protein DAP12. The
combined data demonstrate a critical role of intramembranous
proteolytic processing by -secretase in the signaling of
TREM2 and thus, provide a functional link between both AD-
associated factors.
EXPERIMENTAL PROCEDURES
Chemicals—Unless noted otherwise, all chemicals used for
the described experiments were purchased in per analysi grade
from Sigma-Aldrich, Roche Applied Science, Carl Roth
(Karlsruhe, Germany), or Applichem (Darmstadt, Germany).
Primers for cloning were obtained from Sigma-Aldrich, and
restriction enzymes were from Fermentas (St. Leon-Rot, Ger-
many). The radiochemicals were from Hartmann Analytic
(Braunschweig, Germany). The following antibodieswere used:
anti-HA and anti--actin (Sigma-Aldrich), 9E10 against c-myc
(Developmental Studies Hybridoma Bank, Iowa City, IA), anti-
FLAG (Sigma-Aldrich), anti-GFP (Roche Applied Science),
anti-mouse IgG and anti-rabbit IgG antibody conjugated with
horseradish peroxidase (Sigma-Aldrich), anti-mouse IgG and
anti-rabbit IgG antibody conjugated with Alexa Fluor 488 or
Alexa Fluor 546 (Molecular Probes).
cDNA Constructs—For cloning of the different TREM2 and
DAP12 constructs, specific primers containing HindIII, XhoI,
or SfiI restriction sites were designed and used to amplify the
corresponding DNA by PCR. For cloning of the phosphosite
mutants of DAP12, internal primers were designed containing
base exchanges generating base triplets for Phe at amino acid
positions 92 and 103. The sequences of all primers are available
upon request. Amplified DNA fragments were digested with
HindIII, XhoI, or SfiI and ligated into pSecTag Hygro B vector
using T4 ligase. Chemically competent Escherichia coli DH5
were transformed with plasmid DNAs and spread on LB agar
supplemented with antibiotics. Single colonies were used to
inoculate 2 ml of LB medium supplemented with antibiotics
and grown overnight at 37 °C. After plasmid preparation, the
sequence of the cloned DNA was checked by sequencing. The
PIP2-sensor GFP-C1-PLC-PH was a gift from Tobias Meyer
(Addgene plasmid 21179).
Cell Culture and Transfection—Both HEK293 and COS7
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) Glutamax containing 4.5 g/liter D-glucose (Invitro-
gen) supplemented with 10% fetal calf serum (FCS; PAN-Bio-
tech, Aidenbach, Germany) and 1% penicillin/streptomycin
solution (50 units/ml penicillin, 50 g/ml streptomycin; Invit-
rogen) at 37 °C, 95% humidity, and 5% CO2. Cells were trans-
fected with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. TREM2was always co-transfected
with DAP12 to allow efficient subcellular transport (2).
Immunocytochemistry—Cells, grown on poly-L-lysine-coated
coverslips, were washed with PBS (140 mM NaCl, 10 mM
Na2HPO4, 1.75 mM KH2PO4 in dH2O, pH 7.4) and fixed in 4%
paraformaldehyde in PBS for 10 min. Cells were then washed
three times in PBS and permeabilized with 0.25% Triton X-100
in PBS. Consecutively, cells were blocked with 10% BSA, 0.25%
TritonX-100 in PBS and incubatedwith primary and secondary
antibodies in 0.125% Triton X-100 in PBS supplemented with
5% BSA. Finally, cells were embedded on a microscope slide
with ImmuMount (Thermo Scientific). To selectively detect
cell surface proteins, cells were stained prior to fixation. For this
purpose, cells were kept on ice during the whole staining pro-
cedure. For blocking, 10% BSA in DMEM was used. Primary
and secondary antibodies were diluted in DMEMwith 5% BSA.
All washing steps were conducted with DMEM, and cells were
finally fixed in 4% PFA in PBS. Cells were analyzed by fluores-
cence microscopy (AxioVert 200; Zeiss) equipped with a plan-
Apochromat 63/0.75 objective and an Axiocam MRm cam-
era). Images were acquired and processed using AxioVision 4.8
software (Zeiss).
Protein Extraction—For total protein extraction, cells were
rinsed in 0.8ml of STEN lysis buffer (50mMTris, 150mMNaCl,
2 mM EDTA, 1% Nonidet P-40, 1% Triton X-100 in dH2O, pH
7.4) for 15 min on ice. The homogenates were cleared by cen-
trifugation for 15 min at 16,000 rcf and 4 °C. For isolation of
cellular membranes, cells were incubated in hypotonic buffer
(10 mM Tris, 1 mM EDTA, 1 mM EGTA, dH2O, pH 7.6) for 15
min on ice, followed by passing the suspension through a needle
15 times. Cell debris and nuclei were pelleted by centrifugation
(10 min at 300 rcf and 4 °C), and the supernatant was further
centrifuged at 16,000 rcf for 60 min to obtain a membrane pel-
let. The pellet was then lysed in STEN lysis buffer for 15min on
ice.
In Vitro -Secretase Activity Assay—In vitro -secretase
activity assays were performed as described previously (18).
Briefly, isolated cellular membranes were resuspended in 150
mM citric buffer, pH 6.4. The reaction mixture was incubated
for 2 h at 37 °C in the absence or presence of 10 M DAPT and
then centrifuged (16,000 rcf) for 1 h at 4 °C. Pellets and super-
natants were separated by SDS-PAGE and proteins detected by
Western immunoblotting.
Precipitation of Soluble Proteins with Trichloroacetic Acid
(TCA)—Cell culture supernatants were collected and cleared
from cellular debris by centrifugation for 10 min at 300 rcf.
Sodium desoxycholic acid was added to a final concentration of
0.02% and incubated for 15 min. TCAwas then added to a final
concentration of 10%, and the mixtures were incubated for 1 h
on ice. Precipitated proteins were collected by centrifugation
for 15min at 16,000 rcf and 4 °C andwashed twicewith ice-cold
acetone. The washed pellets were air-dried, resuspended in 35
l of Tris-SDS buffer (50 mM Tris, 1% SDS in dH2O), and incu-
bated for 10min at 50 °C. Finally, SDS-sample bufferwas added,
and samples were subjected to separation by SDS-PAGE.
Biotinylation of Cell Surface Proteins—Cellswere cultured on
poly-L-lysine-coated dishes. After two washes with ice-cold
PBS, cells were incubated with 2 ml of biotin solution (0.5
mg/ml sulfo-NHS-biotin (Thermo Scientific) in PBS) for 30
min on ice under constant gentle shaking. Cells were then
washed three times with 20mM glycine in PBS; the last washing
solution was kept on cells for 15 min. Cells were then lysed in
900 l of STEN lysis buffer for 15 min on ice. After centrifuga-
tion for 10 min at 16,000 rcf and 4 °C, 50 l of streptavidin-
agarose (Invitrogen) was added to the lysates, and the mixture
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was incubated overnight at 4 °C on an overhead shaker. Finally,
the streptavidin-agarose waswashed four times for 10min each
with STENbuffer (50mMTris, 150mMNaCl, 2mMEDTA, 0.2%
Nonidet P-40 in dH2O, pH 7.6), pelleted by centrifugation for 3
min at 600 rcf and 4 °C and resuspended in SDS-sample buffer
and separated by SDS-PAGE.
Radiolabeling with 32Pi upon Activation of TREM2—Cells
were grown on poly-L-lysine-coated dishes and starved in phos-
phate-free DMEM (Invitrogen) for 1 h. After incubation for 1 h
in labeling medium (phosphate-free DMEM supplemented
with 0.5mCi/dish 32Pi) at 37 °C, 5% CO2, TREM2was activated
by 10 g/ml anti-myc antibody. 200 M orthovanadate was
used to stabilize the DAP12 phosphorylation. The cells were
then incubated for another hour, washed once with PBS, and
washed in 1 ml of STEN lysis buffer. DAP12 was then precipi-
tated from the cleared lysateswith anti-HAantibody coupled to
protein G-Sepharose beads (Invitrogen). The beads were pel-
leted by centrifugation for 2min at 9300 rcf and 4 °C before they
werewashed oncewith STEN-NaCl buffer (50mMTris, 500mM
NaCl, 2 mM EDTA, 0.2% Nonidet P-40 in dH2O, pH 7.6) and
twice with STEN buffer. Finally, beads were resuspended in 20
l of SDS-sample buffer.
Analysis of PIP2—COS7 cells were plated on Ibidi -dishes
and were transfected with the PIP2 sensor, TREM2, and
DAP12. Cells were then incubated for 24 h in presence or
absence of 10MDAPT. The fluorescence intensity of the PIP2
sensor was recorded every 10 min for 20 min in a time lapse
setup. After adding c-myc antibody (10 g/ml) to activate
TREM2, fluorescence intensity was further recorded every 10
min for 100 min. For quantification, the average fluorescence
intensity before antibody application was set as F0, and F/F0
was calculated for every time point.
Densitometric Quantification and Statistical Analysis—Pro-
tein signals were quantified by densitometric analysis using
Quantity One software (Bio-Rad). Statistical analyses were
carried out by a two-sided Student’s t test (t test). For compar-
ison of more than two individual groups, one-way analysis of
variance with a Newman-Keuls ad hoc test was used. If not
indicated otherwise, the diagrams show mean values  corre-
sponding S.E. of three independent experiments. Significance
values are indicated by asterisks: *, p 0.05; **, p 0.01; ***, p
0.001.
RESULTS
Proteolytic Shedding of the TREM2 Ectodomain—TREM2
has been identified as a novel strong risk factor for LOAD, but it
is unknown how TREM2 contributes to the disease (10, 11). To
characterize the cellular metabolism of TREM2, we first ana-
lyzed whether this receptor undergoes proteolytic processing
that might regulate its expression levels at the cell surface.
Because the endogenous ligand of TREM2 is unknown and
available antibodies do not reliably detect endogenously
expressed TREM2, we first generated a TREM2 variant that
carries a myc tag at the ectodomain, and an additional GFP-tag
at the intracellular C terminus (myc-TREM2-GFP; Fig. 1A). To
enable efficient transport of TREM2 to the cell surface, this
TREM2 variant was co-expressed along with its adaptor mole-
cule DAP12, which was tagged with a hemagglutinin epitope
(DAP12-HA). As members of the matrix metalloprotease
(MMP) family or the A Disintegrin And Metalloprotease
(ADAM) family are major proteases involved in the cleavage of
cell surface proteins, COS7 cells were incubated in absence or
presence of batimastat, a well known inhibitor of proteases of
both families (19, 20). In control cells, only low levels of cell
surface-localized TREM2 were detected, although GFP detec-
tion indicated robust cellular expression (Fig. 1A). Interest-
ingly, treatment with batimastat resulted in a 3-fold increase
of cell surface-localized TREM2 (313.4  18.8% versus 100 
10.7%; Fig. 1A).
Western immunoblotting further confirmed the inhibition
of TREM2 ectodomain shedding by batimastat, as the treat-
ment increased the levels of full-length TREM2 (TREM2 FL) in
the membrane fraction and decreased the amount of the
secreted TREM2 ectodomain variants (TREM2 ECD; 14.6 
2.4% versus 100  14.6%; Fig. 1B). Because TREM2 contains
putative glycosylation sites in its ectodomain, the different
bands for the full-length receptor in the membrane and the
extracellular fragment in the culture supernatant might repre-
sent different glycosylation variants. We also detected a lower
molecular mass species of TREM2 of about 48 kDa, likely rep-
resenting a C-terminal fragment of TREM2 tagged with GFP
(TREM2 CTF-GFP; Fig. 1B). Consistent with decreased ect-
odomain shedding, levels of the TREM2 CTF were decreased
upon incubation with batimastat (17.2  0.5% versus 100 
10.6%; Fig. 1B). These combined results indicate that TREM2
undergoes ectodomain shedding by a protease of the ADAMor
MMP family.
Intramembranous Cleavage of the TREM2 C-terminal Frag-
ment by-Secretase—Having established the ectodomain shed-
ding of TREM2, we next tested whether the resulting mem-
brane-tethered TREM2 CTF represents a substrate for
-secretase, a major protease complex involved in intramem-
branous cleavage of type I membrane proteins after precedent
removal of globular ectodomains. To enable the specific detec-
tion of proteolytic fragments, we transfectedHEK293 cells with
a TREM2 FL variant carrying a FLAG- and myc/His epitope at
its N and C terminus, respectively (Fig. 2A). Western immuno-
blotting with anti-c-myc antibodies revealed the expression of
35-kDa and 17-kDa TREM2 variants, consistent with the
expectedmolecular masses of full-length TREM2 and its mem-
brane-bound CTF, respectively (without a GFP tag, compare
with Fig. 1). Interestingly, the pharmacological inhibition of
-secretase with DAPT led to a significant increase of TREM2
CTFs (239.6  10.8% versus 100  18.2%; Fig. 2A). To further
confirm these findings, the effect of genetic -secretase inhibi-
tion on TREM2 CTF accumulation was investigated. HEK293
cells stably overexpressing wild type (WT) or a dominant neg-
ative (DN) variant of presenilin 1 (PS1) were co-transfected
with cDNAs encodingTREM2andDAP12 (Fig. 2B). Consistent
with the pharmacological-secretase inhibition, the expression
of the PS1DNmutant also led to significant TREM2CTF accu-
mulation compared with PS1 WT-expressing cells (184.9 
0.5% versus 100  6%).
It has been shown that -secretase selectively processes
C-terminal stubs of proteins with short (10–15 amino acids)
ectodomains (21, 22). Thus, we next generated a TREM2 vari-
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ant lacking the TREM2 ectodomain (FLAG-TREM2ECD-
myc/His). Expression of this construct revealed amarked accu-
mulation in HEK293 PS1 DN compared with HEK293 PS1WT
cells (258.8  43.5% versus 100  16.7%; Fig. 2C). To further
prove processing of TREM2 by -secretase, we performed in
vitro -secretase cleavage assays using the myc-TREM2-GFP
construct (Fig. 2D). By Western immunoblotting we detected
the TREM2 CTF fused to GFP (48 kDa) in the pellet fraction
containing cellular membranes. Notably, in the supernatant
fraction that should contain soluble products released from the
membrane upon -secretase cleavage, we detected a TREM2
band of 35 kDa, fitting well with the putative size of the
TREM2 ICD fused toGFP. This bandwas strongly decreased in
presence of DAPT (Fig. 2D). Together, these data demonstrate
that the C-terminal fragment of TREM2 generated by ectodo-
main shedding represents a substrate for -secretase.
Accumulation of TREM2 CTFs at the Cell Surface upon Inhi-
bition of -Secretase—-Secretase cleaves its substratesmainly at
the cell surface or intracellular endocytic compartments (23–25).
To specifically test whether inhibition of -secretase results in
accumulation of TREM2 CTF at the cell surface, we first carried
out cell surface biotinylation experiments upon cell incubation in
absence or presence of the -secretase inhibitor DAPT (Fig. 3A).
The pulldown of biotinylated proteins and subsequent detection
of TREM2 FL or its CTF demonstrated a strong accumulation of
the TREM2CTF and a less pronounced increase of TREM2 FL at
the cell surface upon -secretase inhibition (Fig. 3A). To further
confirm the specific accumulation of TREM2 CTF at the cell
surface, COS7 cells were co-transfected with FLAG-tagged
TREM2ECD-myc/His and DAP12-HA and incubated in
absence or presence of DAPT for 24 h. The specific immunocyto-
chemical detection of the TREM2 CTF at the plasma membrane
FIGURE 1. Shedding of the TREM2 ectodomain. A, COS7 cells were co-transfected with DAP12-HA and myc-TREM2-GFP (scheme). After 24 h, cells were treated
with 10 M batimastat or dimethyl sulfoxide as solvent control for 1 h. Surface localization of TREM2 was visualized by surface staining using anti-myc primary
and Alexa Fluor 594-coupled secondary antibodies (see “Experimental Procedures”). Scale bars represent 20 m. Bar chart shows quantification of TREM2
signals in randomly chosen areas of 75  75 pixels (Ctrl, n  25; batimastat, n  40 areas). B, HEK293 cells co-transfected with FLAG-DAP12-HA and myc-
TREM2-GFP were incubated in the presence or absence of batimastat (10 M) for 24 h in serum-free medium. Cellular membranes were isolated and condi-
tioned medium precipitated with TCA. Proteins were separated by SDS-PAGE, and TREM2 was detected by Western immunoblotting with anti-GFP (mem-
brane) or anti-myc antibodies (medium). The different bands detected for TREM2 in membrane fractions and for the secreted TREM2 ECD in medium might
represent different glycosylation state variants. Bar charts show the quantification of TREM2 ECD/FL ratios (left panel) and TREM2 CTF/FL ratios (right panel) (n 
3). Statistical analysis was done by two-tailed t test. Error bars, S.E. **, p  0.01; ***, p  0.001.
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FIGURE 2. Cleavage of TREM2 C-terminal fragments by -secretase. A–C, native HEK293 cells (A) or HEK293 cells stably overexpressing PS1 WT or PS1 DN
variants (B and C) were co-transfected with FLAG-DAP12-HA and FLAG-TREM2-myc/His (A and B) or with FLAG-TREM2ECD-myc/His (C) and cultured for 24 h.
Membrane proteins were separated by SDS-PAGE, and TREM2 variants were detected by Western immunoblotting with anti-myc antibody. Bar charts show the
quantification of TREM2 CTF/FL ratios (A and B; n  3) or relative levels of TREM2 CTFs (C; n  2). Statistical determination was done by a two-tailed t test (A) (n 
3) or one-way analysis of variance ANOVA (B) ( n  3). D, in vitro -secretase activity assay. Membranes of HEK293 cells expressing myc-TREM2-GFP were isolated
and incubated for 2 h in the absence or presence of 10 M DAPT. Reaction mixtures were separated by centrifugation into membrane (Membr.) and supernatant
(Sup.) fractions. TREM2 CTF-GFP in the membrane fraction and soluble TREM2 ICD-GFP in the supernatant was detected by Western immunoblotting with
anti-GFP antibodies. The soluble TREM2 ICD-GFP was strongly reduced after incubation with DAPT. Bar chart shows the quantification of TREM2 ICD/CTF ratios
(n  2). Error bars, S.E. **, p  0.01; ***, p  0.001.
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via its extracellularFLAGepitope revealedapunctuatedpattern in
thecontrol cells, typical for cell surface-localizedproteins (Fig. 3B).
Cell treatment with DAPT increased the surface levels of TREM2
CTFs (319.2  40.8% versus 100  10.32%). Together with the
biochemical experiments (Fig. 3A), thesedatademonstratea selec-
tive accumulationofTREM2CTFat the cell surfaceupon-secre-
tase inhibition.
Inhibition of -Secretase Impairs the Interaction of TREM2
with Its Signaling Adaptor Protein DAP12—TREM2 interacts
with its co-receptor DAP12 via charged amino acid residues in
their transmembrane domains (2). This electrostatic interaction is
critical for the signaling of activatedTREM2 to its adaptor protein
DAP12. Thus, we next tested whether -secretase inhibition
affects the interaction of TREM2 with DAP12. To allow specific
detection of cell surface-localized complexes of TREM2 CTF and
DAP12, we co-expressed the TREM2ECD variant with a FLAG
tag in the ectodomain and the DAP12-HA-tagged variant (Fig.
4A). After DAPT treatment, living cells were incubated with anti-
FLAG antibodies on ice, fixed, and permeabilized. DAP12 local-
ization was visualized with a specific antibody against the HA tag.
TREM2CTF at the cell surface was localizedmainly in punctae in
untreated control cells (Fig. 4A). Upon -secretase inhibition, the
co-localization between TREM2 CTF and DAP12 increased and
changed from punctuated pattern to larger, spiry structures that
covered substantial areas of the plasma membrane (0.671 
0.0029versus0.4580.0034;Fig. 4A).Thus, accumulatedTREM2
CTFs upon -secretase inhibition induced a redistribution of its
interaction partner DAP12.
The ligand-induced activation of DAP12-interacting full-
length receptors results in phosphorylation ofDAP12within its
ITAMdomain by Src kinase. Therefore, the phosphorylation of
DAP12 upon activation of TREM2 was analyzed with or with-
FIGURE 3. TREM2 CTFs accumulate at the cell surface after -secretase inhibition. A, HEK293 cells were transfected with FLAG-TREM2-myc/His in combi-
nation with FLAG-DAP12-HA and incubated for 24 h in absence or presence of 10 M DAPT. Surface proteins were labeled with sulfo-NHS-biotin for 30 min. Cells
were lysed and biotin-labeled proteins precipitated with streptavidin-coated agarose beads. Aliquots of cell lysates and streptavidin-precipitates were sepa-
rated by SDS-PAGE, and TREM2 was detected by Western immunoblotting with anti-myc antibodies. Treatment with DAPT increases the cell surface expression
of TREM2. Bar graphs show the quantification of TREM2 CTF/FL ratios (n  3). B, COS7 cells were co-transfected with DAP12-HA and FLAG-TREM2ECD-myc/His
and incubated for 24 h in presence or absence of 10 M DAPT. TREM2 CTF was visualized at the cell surface of living cells by anti-FLAG primary and Alexa Fluor
488-coupled secondary antibodies. Bar graph shows the quantification of TREM2 CTF-positive structures in five randomly chosen areas of 75  75 pixels in 10
cells each. Insets show enlarged images of boxed areas. Scale bars represent 20 m. Statistical analyses were done by using a two-tailed t test. Error bars, S.E. *,
p  0.05; ***, p  0.001.
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out -secretase inhibition by in vivo radiolabeling with 32Pi.
After cell lysis, DAP12was immunoprecipitated and phosphate
incorporation analyzed by autoradiography. In control cells,
two weakly phosphorylated variants of DAP12 were detected
(Fig. 4B). 32P radiolabeling strongly increased after the inhibi-
tion of tyrosine phosphatases by orthovanadate, indicating effi-
cient phosphorylation and rapid dephosphorylation of DAP12
upon activation of TREM2 (Fig. 4B). A variant of DAP12 with
mutated phosphorylation sites (DAP12 Y92F/Y103F) did not
undergo phosphorylation, demonstrating the specific labeling
of these tyrosine residues. Interestingly, the inhibition of
-secretase led to a complete suppression of phosphate incor-
poration into the lowermigrating variant of DAP12, even in the
presence of orthovanadate (Fig. 4B), demonstrating impaired
signaling of TREM2 to its adaptor protein DAP12.
Accumulation of the TREM2 C-terminal Fragment Impairs
Phosphatidylinositol Metabolism—DAP12 has been previously
linked to the activation of PLC, which hydrolyzes PIP2 to ino-
sitol 1,4,5-trisphosphate and diacylglycerol (7, 26). Thus,
impairment ofDAP12 signaling by-secretase inhibitionmight
decrease PLC activity thereby increasing PIP2 levels in the cell.
To test this hypothesis, we analyzed changes in PIP2 levels in a
time lapse experiment after activation of TREM2-DAP12 sig-
naling by cross-linking TREM2 with anti-myc antibodies. To
visualize PIP2 in this experimental setup, we took advantage of
a previously described PIP2 sensor, consisting of the pleckstrin
homology domain of PLC fused to GFP (27, 28). COS7 cells
were co-transfected with this PIP2 sensor, myc-TREM2-
mCherry and DAP12-HA and incubated for 24 h in the pres-
ence or absence of DAPT. In response to TREM2-DAP12 acti-
vation by antibody cross-linking, the fluorescence intensity
remained constant in DAPT-treated cells, with only a small
decrease due to photobleaching (Fig. 5A, blue line). In contrast,
the fluorescence intensity in cells incubated without DAPT
steadily decreased after application of antibody (Fig. 5A, red
line), indicating a reduction of PIP2 levels. Cells expressing the
PIP2 sensor alone did not respond to antibody treatment (Fig.
5A, gray line), indicating specific signal transduction via
TREM2. Together, these results indicate that the inhibition of
-secretase interferes with TREM2-dependent regulation of
PIP2 levels at the plasma membrane.
DISCUSSION
Here, we show that TREM2 represents a novel substrate for
-secretase and thereby unraveled a functional connection of
two important factors involved in the pathogenesis of AD. The
FIGURE 4. Inhibition of -secretase alters the interaction of TREM2 with DAP12 and impairs DAP12 phosphorylation. A, COS7 cells expressing DAP12-HA and
FLAG-TREM2ECD-myc/His (scheme) were incubated in the presence or absence of 10 M DAPT for 24 h. Surface TREM2 CTF was visualized using anti-FLAG primary
and Alexa Fluor 594-coupled secondary antibodies. After the specific cell surface staining, cells were fixed and permeabilized, and total DAP12 was stained using
anti-HA primary and Alexa Fluor 488-coupled secondary antibodies. Co-localization of DAP12 and TREM2 CTF was analyzed by the Pearson co-efficient in four
randomly chosen areas of four different cells. Insets show enlarged images of boxed areas. Scale bars represent 20 m. Statistical analysis was done by two-tailed t test
(p  0.001). Error bars, S.E. ***, p  0.001. B, HEK293 cells co-expressing myc-TREM2 and DAP12-HA were incubated in presence or absence of 10 M DAPT for 24 h. The
DAP12 Y92F/Y103F-HA variant lacking potential phosphorylation sites in the ITAM domain was co-transfected with TREM2 as a control (last lane). Cells were starved
for 30 min in phosphate-free medium and then incubated with 32Pi for 1 h. TREM2 was activated by incubation with 10 g/ml anti-myc antibody. After further
incubation for 1 h in the presence or absence of 200 M orthovanadate (OV), cells were lysed, and DAP12 was precipitated with anti-HA antibodies. Proteins were
separated on a Tris-Tricine gel and transferred onto a nitrocellulose membrane. Radiolabeled proteins were visualized by autoradiography (upper panel, 32P). After
exposure, DAP12-HA was detected on the same membrane by Western immunoblotting with anti-HA antibodies (lower panel, WB).
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-secretase complex contains presenilin-1 or -2 as the catalyt-
ically active component (29–32). Importantly, mutations in the
presenilins are the most common cause of familial early onset
AD and have been linked to frontotemporal lobe dementia as
well (33). -Secretase cleaves the amyloid precursor protein
and thus, plays a direct role in amyloid- generation (34, 35).
Besides amyloid precursor protein, many additional protein
substrates of -secretase have been identified, but their relation
and potential functional connections to AD pathogenesis
remain largely unknown.
The present data demonstrate that the inhibition of -secre-
tase leads to a strong accumulation of the TREM2 CTF at the
cell surface and trapping of its adaptorTYROBP/DAP12,which
then impairs the signaling function of full-length TREM2. We
also show that the full-length TREM2 undergoes ectodomain
shedding before -secretase cleavage and thus represents a
canonical substrate for regulated intramembrane proteolysis.
The initial cleavage of TREM2 by a shedding enzyme results
in the liberation of a globular ectodomain which is a prerequi-
site for further intramembrane cleavage by -secretase.
Although the responsible sheddase remains to be determined,
the efficient inhibition of ectodomain shedding by batimastat
suggests the involvement of metalloproteases of the MMP
and/or ADAM family. Both classes of proteases are highly
FIGURE 5. Impaired DAP12 signaling upon -secretase inhibition affects PIP2 metabolism. A, COS7 cells expressing the PIP2 sensor PH-PLC-GFP in
combination with myc-TREM2-mCherry and DAP12-HA (scheme) were incubated for 24 h in presence or absence of 10 M DAPT. Fluorescence of the PIP2
sensor was measured every 10 min for 120 min. c-myc antibodies (10 g/ml) were applied after 20 min (dashed line). The graph shows the quantification of
fluorescence intensities plotted as F/F0 against time for cells incubated with (blue line) or without DAPT (red line). The fluorescence in cells expressing the PIP2
sensor alone served as control (gray line). Statistical determination was done by two-way analysis of variance (DAPT, n  4; DAPT, n  6). Error bars, S.E. **,
p  0.01; ***, p  0.001. ns, not significant. B, schematic drawing shows the proposed role of TREM2 processing in membrane-proximal signaling with either
active (upper panel) or inhibited -secretase (lower panel). In absence of ligand (upper panel, left), the ectodomain of membrane-associated TREM2 FL is cleaved
by a sheddase. The resultant TREM2 CTF is then cleaved by -secretase. In the presence of ligand, TREM2 signals to DAP12 (upper panel, right). Upon inhibition
of -secretase, TREM2 CTFs accumulate after ectodomain shedding (lower panel, left). Accumulated CTFs trap DAP12 co-receptors, thereby preventing the
interaction with full-length TREM2 receptors (lower panel, right; see “Discussion” for details). L, ligand; , -secretase; P, phosphate.
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expressed in microglia cells (36) and can cleave several impor-
tant receptors and cytokines (37).
Soluble variants of TREM2 and its homolog TREM1 have
been detected in human cerebrospinal fluid (CSF) (38) or in
blood of septic shock patients (39, 40). Although our data
clearly support a release of soluble TREM2 by proteolytic shed-
ding, additional mechanisms have also been proposed, includ-
ing alternative splicing of the TREM2mRNA that could lead to
shortened variants without the transmembrane domains (41).
However, as metalloprotease inhibitors also decreased the lev-
els of soluble TREM1 variants (39, 42), proteolytic shedding
appears to be a general mechanism for the release of both
TREM receptors. After shedding of the ectodomain, the
remaining TREM2CTF is further degraded by -secretase (Fig.
5B). Interestingly, presenilin has been previously shown to be
involved in microglial phagocytosis and migration, but the
molecularmechanisms remain to be identified (43, 44). Thus, it
will be important to investigate further whether these observed
effects also involve misprocessing of TREM2.
Our data demonstrate that decreased processing of TREM2
CTFs by -secretase indeed interferes with TREM2-dependent
signaling. The findings also indicate that the accumulation of
TREM2 CTFs traps the adaptor DAP12 at the cell membrane,
thereby decreasing its availability to interact with functional
full-length TREM2 (see Fig. 5B). It is important to note that the
TREM2 CTF generated by ectodomain shedding still contains
themotif for the electrostatic interactionwithDAP12. Interest-
ingly, the phosphorylation of DAP12 upon activation of the
full-length receptor was strongly decreased in cells with accu-
mulated TREM2 CTF upon -secretase inhibition. Moreover,
upon stimulation of TREM2, PIP2 metabolismwas impaired by
inhibition of -secretase. Alterations in phosphoinositide levels
have been previously observed in cell lines expressing preseni-
lin-1 FAD-associated mutations, but the molecular mecha-
nisms were not identified (45, 46). Because DAP12 can nega-
tively regulate phosphoinositol 3-kinase (PI3K) (47–49) and
activate PLC (7, 26), our data suggest that impaired activation
of DAP12 upon inhibition of -secretase could either result in
decreased suppression of PI3K or decreased activity of the
PLC and thus, elevation of PIP2 levels at the plasma
membrane.
It is interesting to note that the recently identified rare vari-
ants of TREM2, which significantly increase the risk of AD,
might result in a loss of function, either by introduction of a
stop codon (p.Q33X variant) or by affecting ligand binding
(p.R47H variant) (10, 11). Thus, these mutations might also
impair signaling to DAP12.
Together, the data from our study demonstrate that TREM2,
a novel risk factor for LOAD, and the presenilins, the most
common factor for familial early onset AD, are both involved in
the same signaling pathway. Thus, it will be interesting to fur-
ther investigate the role of TREM2 and -secretase inmicroglia
and neuroinflammatory processes associated with AD and
frontotemporal lobe dementia.
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